医学
抗磷脂综合征
血栓性微血管病
伊库利珠单抗
2019年冠状病毒病(COVID-19)
血栓形成
免疫学
临床试验
抗体
重症监护医学
疾病
补体系统
内科学
传染病(医学专业)
作者
Xin Wang,Elena Gkrouzman,Danieli Andrade,Laura Andréoli,Medha Barbhaiya,H. Michael Belmont,D. Ware Branch,Guilherme Ramires de Jesús,Maria Efthymiou,Roberto Ríos‐Garcés,Maria Gerosa,Georges El Hasbani,Jason S. Knight,Pier Luigi Meroni,Giulia Pazzola,Michelle Petri,Jacob H. Rand,Jane E. Salmon,Maria G. Tektonidou,Anǵela Tincani
出处
期刊:Lupus
[SAGE Publishing]
日期:2021-12-01
卷期号:30 (14): 2276-2285
被引量:28
标识
DOI:10.1177/09612033211062523
摘要
Coronavirus disease 2019 (COVID-19) is associated with a high rate of thrombosis. Prolonged activated partial thromboplastin times (aPTT) and antiphospholipid antibodies (aPL) are reported in COVID-19 patients. The majority of publications have not reported whether patients develop clinically relevant persistent aPL, and the clinical significance of new aPL-positivity in COVID-19 is currently unknown. However, the reports of aPL-positivity in COVID-19 raised the question whether common mechanisms exist in the pathogenesis of COVID-19 and antiphospholipid syndrome (APS). In both conditions, thrombotic microangiopathy resulting in microvascular injury and thrombosis is hypothesized to occur through multiple pathways, including endothelial damage, complement activation, and release of neutrophil extracellular traps (NETosis). APS-ACTION, an international APS research network, created a COVID-19 working group that reviewed common mechanisms, positive aPL tests in COVID-19 patients, and implications of COVID-19 infection for patients with known aPL positivity or APS, with the goals of proposing guidance for clinical management and monitoring of aPL-positive COVID-19 patients. This guidance also serves as a call and focus for clinical and basic scientific research.
科研通智能强力驱动
Strongly Powered by AbleSci AI